Alnylam Pharmaceuticals Advances Phase 2 Trial for CAA Treatment

Alnylam Pharmaceuticals ((ALNY)) announced an update on their ongoing clinical study.

Study Overview: Alnylam Pharmaceuticals is conducting a Phase 2 trial titled A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Intrathecally Administered ALN-APP in Patients With Cerebral Amyloid Angiopathy (CAA). The study aims to assess the impact of ALN-APP on CAA disease progression and evaluate its safety and tolerability in adult patients with sporadic and Dutch-type CAA.

Intervention/Treatment: The study tests ALN-APP, an experimental drug administered intrathecally, designed to slow CAA progression. A placebo is used for comparison, with participants potentially receiving ALN-APP in an optional extension period.

Study Design: This interventional study is randomized with a parallel assignment model. It employs quadruple masking, ensuring participants, care providers, investigators, and outcomes assessors are blinded. The primary purpose is treatment-focused.

Study Timeline: The study began on May 17, 2024, with primary completion and estimated completion dates yet to be announced. The last update was submitted on July 15, 2025, indicating ongoing recruitment and progress.

Market Implications: This study’s progress could influence Alnylam Pharmaceuticals’ stock, as positive outcomes may boost investor confidence and market performance. The competitive landscape in CAA treatment remains a critical factor, with advancements potentially positioning Alnylam as a leader in this niche.

The study is ongoing, with further details available on the ClinicalTrials portal.